ReviewFrontiers in health services2023

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment.

Remziye Zaim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.